TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3323072

Group type: EXPERIMENTAL
Intervention: terbutaline (10 mg/day) and metoprolol (200 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: metoprolol (200 mg/day) alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: terbutaline (10 mg/day) alone
Number of subjects: 36
Study: 31362066

Group type: COMPARATOR
Intervention: Control group with additional follow-up assessments
Number of subjects: 516
Study: 30896618

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Preserved renal function
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CKD with LVEF <50%
Number of subjects: 918

Group type: COMPARATOR
Intervention: Preserved renal function with LVEF <50%
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CKD
Number of subjects: 918
Study: 27922921

Group type: EXPERIMENTAL
Intervention: Muscle relaxation and therapeutic walking for 3 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 25912899

Group type: EXPERIMENTAL
Intervention: Biventricular pacing with intrinsic pacing (BiV + intrinsic pacing)
Number of subjects: 44
Study: 23910665

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 600 mg/d for 7 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg/d for 7 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg on day 7
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 88
Study: 21270330

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting normoglycemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolerating excessive hyperglycemia
Number of subjects: 0
Study: 19449244

Group type: EXPERIMENTAL
Intervention: Extended letter fluency test (2 minutes per trial)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard letter fluency test (1 minute per trial)
Number of subjects: 60
Study: 16458451

Group type: EXPERIMENTAL
Intervention: Low dose levamisole (LMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 15078039

Group type: EXPERIMENTAL
Intervention: Masked repetition priming with a prime validity of 0.8 (high proportion of trials with repetition primes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Masked repetition priming with a prime validity of 0.2 (low proportion of trials with repetition primes)
Number of subjects: 0
Study: 11478456

Group type: EXPERIMENTAL
Intervention: Ivermectin (100 ug/kg body weight, 2 doses, 3 months apart)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 73
Study: 9757894

Group type: EXPERIMENTAL
Intervention: Measurement of the diameter of the external cervical os
Number of subjects: 25
Study: 7872409

Group type: EXPERIMENTAL
Intervention: Schema-based attention hypothesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schema-based retrieval hypothesis
Number of subjects: 0
Study: 3045069

Group type: EXPERIMENTAL
Intervention: Topical therapy with vidarabine sodium phosphate in an aqueous gel
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 134
Study: 30721647

Group type: EXPERIMENTAL
Intervention: Single session, clinic-based intervention promoting condom use
Number of subjects: 277

Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 277
Study: 29686147

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 1066
Study: 27145159

Group type: EXPERIMENTAL
Intervention: Atrial electromechanical conduction time (EMT‐ε) measured with speckle tracking echocardiography after pulmonary vein isolation (PVI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EMT‐ε shortening at 6 months after PVI
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects (10 subjects)
Number of subjects: 46
Study: 24205991

Group type: EXPERIMENTAL
Intervention: γ-cyclodextrin nanoparticle eye drops containing 3% dorzolamide, given once a day (QD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Trusopt given three times a day (TID)
Number of subjects: 17
Study: 22998554

Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 20631014

Group type: EXPERIMENTAL
Intervention: PTH (1‐34) for 14 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 17610013

Group type: EXPERIMENTAL
Intervention: Prolonged stage transition duration (STD) in aspirating stroke patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Prolonged stage transition duration (STD)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonaspirating stroke participants
Number of subjects: 66
Study: 16111499

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study: 12501952

Group type: EXPERIMENTAL
Intervention: Dynamic AFOs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Static AFOs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 14
Study: 9703563

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg papaverine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8580278

Group type: EXPERIMENTAL
Intervention: Budesonide enema (2 mg/100 mL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 5-ASA enema (mesalazine 1 g/100 mL)
Number of subjects: 97
Study: 2293938

Group type: EXPERIMENTAL
Intervention: One-step application of a water-insoluble iodophor-in-alcohol solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional two-step method using aqueous iodophors (five-minute scrub followed by paint)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional two-step method using aqueous iodophors
Number of subjects: 60
Study: 33455

Group type: EXPERIMENTAL
Intervention: Thiopentone (3.5 mg/kg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Methohexitone (1 mg/kg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low-dose ketamine (1 mg/kg)
Number of subjects: 3
Study: 31764794

Group type: EXPERIMENTAL
Intervention: Ball-point slide-type interbody distractor
Number of subjects: 59

Group type: COMPARATOR
Intervention: Posterior reduction and internal fixation (control)
Number of subjects: 59
Study: 27753282

Group type: EXPERIMENTAL
Intervention: Test formulation 2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test formulation 3
Number of subjects: 18

Group type: COMPARATOR
Intervention: Innovator product
Number of subjects: 18
Study: 26083828

Group type: EXPERIMENTAL
Intervention: Aleph inactivated split influenza vaccine
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control vaccine (recombinant hepatitis B)
Number of subjects: 641
Study: 23405952

Group type: EXPERIMENTAL
Intervention: Videoconference parent training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Face-to-face parent training
Number of subjects: 22
Study: 20825844

Group type: EXPERIMENTAL
Intervention: Handheld feedback device
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no feedback device)
Number of subjects: 25
Study: 20043525

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 microg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intramuscular syntometrine (syntocinon 10 IU + ergometrine 0.5 mg)
Number of subjects: 140
Study: 17374344

Group type: EXPERIMENTAL
Intervention: Boiled extract of Carum copticum (0.125 ml/kg and 0.25 ml/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15596918

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens in phase III clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response rates (RR) for most advanced cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responders vs. nonresponders
Number of subjects: 0
Study: 11717601

Group type: EXPERIMENTAL
Intervention: Duett vascular sealing device
Number of subjects: 0
Study: 9150013

Group type: EXPERIMENTAL
Intervention: Sympathetic blockade with 0.5% epidural bupivacaine and 0.5‐1% isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with nitrous/narcotic and inhalation anesthesia for maintenance
Number of subjects: 40
Study: 7899032

Group type: EXPERIMENTAL
Intervention: Moving random‐pixel arrays (RPAs) used to study MAE for translational texture motion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subpopulation of local motion sensors contributing to the MAE.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of MAEs generated at different eccentricities.
Number of subjects: 0
Study: 2949876

Group type: EXPERIMENTAL
Intervention: qi‐regulating; blood‐activating and wind‐dispelling Chinese medicine (A group, 100 cases)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: cortical hormone (B group, 51 cases)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: yin‐nourishing; blood‐activating and wind‐dispelling Chinese medicine (C group, 53 cases)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Buguzhi tincture (D group, 28 cases)
Number of subjects: 232
Study: 29440005

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg·d‐1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg·d‐1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both dapagliflozin and bumetanide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dapagliflozin after 1 week of bumetanide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bumetanide after 1 week of dapagliflozin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined therapy (Dapagliflozin and Bumetanide)
Number of subjects: 42
Study: 26446450

Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23982766

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22724534

Group type: EXPERIMENTAL
Intervention: 2-Hz pulse-modulated radio frequency field
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2-Hz pulsed magnetic field
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 25
Study: 15882209

Group type: EXPERIMENTAL
Intervention: Binary system containing block copolymers as toothpaste slurry rinse
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ternary system containing block copolymers and polypeptide as toothpaste slurry rinse
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Binary system containing block copolymers as solution rinse
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ternary system containing block copolymers and polypeptide as solution rinse
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Conventional fluoride toothpaste rinse
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chlorhexidine rinse (positive control)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Water rinse (negative control)
Number of subjects: 21
Study: 12186234

Group type: EXPERIMENTAL
Intervention: Videotape of an expert model performing the skills
Number of subjects: 116

Group type: COMPARATOR
Intervention: Videotaped replay of their own performance
Number of subjects: 116
Study: 10192700

Group type: EXPERIMENTAL
Intervention: High-grade oligodendroglial tumors
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low-grade oligodendroglial tumors
Number of subjects: 47
Study: 7775634

Group type: EXPERIMENTAL
Intervention: Oxandrolone 2.5 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone 50 mg monthly IM injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All active treatments (Oxandrolone and Testosterone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 16
Study: 2270749

Group type: EXPERIMENTAL
Intervention: Essential fatty acid therapy (8 x 500 mg capsules per day for 3 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (8 x 500 mg capsules per day for 3 months)
Number of subjects: 63
Study: 7009192

Group type: EXPERIMENTAL
Intervention: Prostacyclin (250 microgram for women, 500 microgram for men)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ultrasonic mist of H2O (group 1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Physical exercise on cycloergometer (group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pneumoallergens (group 3)
Number of subjects: 3
Study: 31813550

Group type: EXPERIMENTAL
Intervention: Barbed suture for closure of enterocolotomy
Number of subjects: 80
Study: 30276208

Group type: EXPERIMENTAL
Intervention: Procedure S (shallow puncture angle using a guidance system)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Procedure C (conventional free-hand method)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Procedure N (needle navigation system)
Number of subjects: 40
Study: 27342264

Group type: EXPERIMENTAL
Intervention: Troponin testing
Number of subjects: 111
Study: 24176494

Group type: EXPERIMENTAL
Intervention: PhtD 30 μg plus AS02V
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: PhtD 10 μg plus alum
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: PhtD 30 μg plus alum
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: PhtD 10 μg plus AS02V
Number of subjects: 297

Group type: COMPARATOR
Intervention: Alum adjuvant
Number of subjects: 297

Group type: COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (23PPV)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 297
Study: 23962655

Group type: EXPERIMENTAL
Intervention: Perturbations towards the preferred leg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Perturbations towards the non-preferred leg
Number of subjects: 39
Study: 21990397

Group type: EXPERIMENTAL
Intervention: Chemotherapy + bevacizumab
Number of subjects: 684

Group type: COMPARATOR
Intervention: Chemotherapy + placebo
Number of subjects: 684
Study: 19067098

Group type: EXPERIMENTAL
Intervention: Harm Minimization (HM) curriculum in grades 8 and 9
Number of subjects: 5266

Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) curriculum in grades 8 and 9
Number of subjects: 5266

Group type: COMPARATOR
Intervention: Control group (usual tobacco use education)
Number of subjects: 5266
Study: 16151770

Group type: EXPERIMENTAL
Intervention: Memory-provoked rCBF-SPECT (MP-SPECT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rest rCBF-SPECT
Number of subjects: 36
Study: 12970130

Group type: EXPERIMENTAL
Intervention: Scheduled second endoscopy 16-24 hours after initial haemostasis
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Scheduled second endoscopy
Number of subjects: 194
Study: 10709150

Group type: EXPERIMENTAL
Intervention: i.v. verapamil
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: oral verapamil
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 14C‐erythromycin breath tests (ERBT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: i.v. and p.o. verapamil
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: p.o. verapamil
Number of subjects: 84
Study: 9166816

Group type: EXPERIMENTAL
Intervention: Hyskon (250 ml 32% dextran 70)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (250 ml)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no fluid)
Number of subjects: 13
Study: 1584259

Group type: EXPERIMENTAL
Intervention: Induction of labor (intracervical application of prostaglandin E2)
Number of subjects: 3407

Group type: COMPARATOR
Intervention: Serial antenatal monitoring (counts of fetal kicks, nonstress tests, assessments of amniotic-fluid volume)
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 3407

Group type: COMPARATOR
Intervention: Serial antenatal monitoring
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Induction of labor and Serial antenatal monitoring
Number of subjects: 3407
Study: 3898904

Group type: EXPERIMENTAL
Intervention: Oral hyposensitization with timothy whole pollen (4,315,000 PNU preseasonally and 8,915,000 PNU total for 6 months)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 30587191

Group type: EXPERIMENTAL
Intervention: Telephone-based weight management and healthy lifestyle service for 6 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 120
Study: 29786336

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 2.5-3.0 mL human umbilical cord MSCs suspension containing (2-3)×10^7 cells, once a month for 2 times
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sodium hyaluronate by intra-articular injection, once a week for 5 times
Number of subjects: 36
Study: 23941193

Group type: EXPERIMENTAL
Intervention: Eccentric-concentric exercise program of the ankle evertors and dorsiflexors, performed 3 days per week for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Eccentric-concentric exercise program of the ankle evertors and dorsiflexors
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 22471128

Group type: EXPERIMENTAL
Intervention: Coiling dragon needling and moving cupping
Number of subjects: 72

Group type: COMPARATOR
Intervention: Prednisone (10 mg orally, once daily for 2 courses)
Number of subjects: 72
Study: 20921898

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa 2a 180 mcg per week + weight-based ribavirin for 12 weeks, followed by full dose PEG for 72 weeks
Number of subjects: 330

Group type: COMPARATOR
Intervention: Observation only for 72 weeks
Number of subjects: 330
Study: 18655992

Group type: EXPERIMENTAL
Intervention: Vigamox 4 times 1 day before surgery plus 1 drop 2 hours preoperatively (Group 1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Vigamox 2 hours before surgery and every 15 minutes in the first hour only (Group 2)
Number of subjects: 74
Study: 15875961

Group type: EXPERIMENTAL
Intervention: Preadmission videotape presentation
Number of subjects: 141

Group type: COMPARATOR
Intervention: No videotape presentation (Control)
Number of subjects: 141
Study: 12622686

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (motivational message, guide to quitting, 10-minute motivational interview, and up to 3 outreach calls in 3 months)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 303
Study: 10575171

Group type: EXPERIMENTAL
Intervention: Intramuscular preexposure vaccination
Number of subjects: 138

Group type: COMPARATOR
Intervention: Intradermal preexposure vaccination (0.1 mL dose)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: All study subjects
Number of subjects: 138
Study: 8793607

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole and 100 mg diclofenac
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 mg diclofenac
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 mg pantoprazole
Number of subjects: 24
Study: 1928632

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ; 4‐28 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Subjective drug effects
Number of subjects: 27
Study: 7047258

Group type: EXPERIMENTAL
Intervention: Carbamazepine (600 mg daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tiapride
Number of subjects: 55
Study: 30789154

Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 28673494

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 50
Study: 26038159

Group type: EXPERIMENTAL
Intervention: Ethanol <10mM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol <20mM
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alprazolam (APZ, 1mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zolpidem (ZLP, 10mg)
Number of subjects: 10
Study: 23821759

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to oxaliplatin-based standard adjuvant chemotherapy regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy regimen without bevacizumab
Number of subjects: 0
Study: 22576838

Group type: EXPERIMENTAL
Intervention: Charnley total hip arthroplasty (THA)
Number of subjects: 35
Study: 18829069

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (20 microg ethinylestradiol + 150 microg norelgestromin daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vaginal ring (15 microg ethinylestradiol + 120 microg etonogestrel daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral contraceptive (30 microg ethinylestradiol + 150 microg levonorgestrel daily)
Number of subjects: 13
Study: 17173849

Group type: EXPERIMENTAL
Intervention: Limbal‐conjunctival autograft transplantation (LCAT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 27
Study: 14712334

Group type: EXPERIMENTAL
Intervention: Flumazenil (2 mg bolus injection)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11549528

Group type: EXPERIMENTAL
Intervention: Oral prednisolone, 20 mg/d for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9802142

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/d + Warfarin
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d (2 h after intake)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aspirin (14 patients identified as secondary aspirin non-responders)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aspirin (2 patients identified as primary aspirin non-responders)
Number of subjects: 143